Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapyNadezda Gracheva, Nicholas P. van der Meulen|EJNMMI Radiopharmacy and Chemistry|2019Cited by 107
<sup>161</sup>Tb Radioimmunotherapy as a Treatment for CD30-Positive LymphomasElisa Rioja-Blanco, Martin Béhé, Christoph Schlapbach et al.|Journal of Nuclear Medicine|2025Cited by 8